CBC Capital Announces Investment in Anhe Jialier, a Leading Chinese Ultrasonic Surgical Device Company

Beijing, August 27, 2021—CBC Group, a healthcare-focused investment firm, recently announced the completion of its investment in Beijing Anhejialier Technology Co., Ltd. (hereinafter referred to as “Anhejialier” or “Anhe”), a company specializing in ultrasonic surgical devices. This investment underscores CBC Group’s strong recognition of Anhe’s capabilities in the ultrasonic scalpel sector and reflects its long-term confidence in and support for high-quality domestic brands.

China Renaissance served as the exclusive financial advisor to the seller in this transaction.

Beijing Anhejialier Technology Co., Ltd. holds a prominent position in the ultrasonic scalpel industry and is one of the few private enterprises capable of breaking the monopoly of imported brands in the Chinese market, with its products widely accepted by clinical users domestically. In this high-barrier niche segment, its independently developed ultrasonic scalpel system leads among domestic brands in terms of market share. The company has established a comprehensive product portfolio, demonstrating superior performance parameters in various core performance benchmark tests. Anhejialier boasts a well-developed R&D, production, and sales system. In terms of technological R&D, the company has built a mature platform to drive product upgrades and iterations. Meanwhile, it possesses a complete and efficient production and supply chain system, resulting in significant quality advantages. Currently, the company has also established an integrated sales network, achieving nationwide market coverage across China.

Regarding this transaction,Zou Jianlong, General Manager of Beijing Anhejialier Technology Co., Ltd.He stated, “We extend our sincere gratitude to CBC Group for its steadfast confidence in Anhe. The robust shareholder support and strategic synergy have laid a solid foundation for Anhe’s rapid future growth. We also thank iCapital for its strong support and professional investment banking services, which provided a powerful guarantee for the successful completion of this transaction.”

Lv Yanxiang, Head of Medical Technology and Healthcare Services at CBC Group“It stated: ‘CBC Group is committed to building a leading domestic minimally invasive treatment platform company through various approaches, including platform incubation, M&A integration, and international cooperation. The investment in Anhejialier represents a further expansion of CBC Group’s presence in the field of minimally invasive treatments, reflecting its long-term confidence in and support for outstanding Chinese brands. As a leading enterprise in China’s ultrasonic scalpel industry, Anhejialier demonstrates significant synergies with other portfolio companies of CBC Group. We are dedicated to fostering the long-term, sustainable development of Anhejialier to better serve patients both domestically and internationally.’”

As the exclusive financial advisor for this transaction,Li Gang, Partner and Co-Head of Healthcare at China Renaissance“The domestic ultrasonic scalpel market is currently dominated by foreign enterprises. Against the backdrop of deepening medical insurance cost containment and the full implementation of centralized procurement, Chinese-branded ultrasonic scalpels will usher in unprecedented development opportunities. We are honored to serve as the exclusive financial advisor to Anhejialier, and we hope that this round of transaction will accelerate the development and commercialization of Anhejialier’s product pipelines.”

Beijing Anhejialier Technology Co., Ltd., established in 2012, specializes in the research, development, and production of ultrasonic surgical scalpel systems with independent intellectual property rights. The company’s products have gained widespread clinical recognition and hold a leading market share among domestic brands. In terms of physicians’ clinical experience and product performance, the Anhe ultrasonic surgical scalpel system aligns well with actual clinical needs, making it one of the few domestic products currently poised to replace imported alternatives. Furthermore, Anhe has developed a clear and comprehensive product pipeline focused on four key areas—laparoscopic surgery, gastrointestinal surgery, urology, and gynecology—with the aim of becoming a leading brand in the field of minimally invasive surgery.

CBC Group is Asia’s largest healthcare investment group, dedicated to value creation and global resource integration. Leveraging a network of world-class scientists and entrepreneurs, CBC Group is committed to enhancing efficiency and driving innovation. It consistently pursues its unique active investment model—characterized by operational drive, platform-based strategies, and global resource mobilization. The firm has spearheaded the founding of more than ten leading healthcare companies, directly engaging in value creation through an “investor-plus-entrepreneur” approach to deliver more inclusive healthcare services and address the growing unmet medical needs worldwide. Established in 2014, CBC Group boasts a strong professional team specializing in investment, healthcare industry expertise, and post-investment management. Headquartered in Singapore, with offices in Shanghai, Hong Kong, New York, Boston, San Diego, Tokyo, and Beijing, the firm focuses on growth-oriented opportunities in multiple core areas of the healthcare sector, including platform development, acquisitions, and credit investments.

China New Economy Investment Banker: iCapital is a leading player in China’s new economy investment banking sector, focusing on three major industries globally: TMT, consumer, and healthcare. In addition to its investment banking services, iCapital manages one RMB-denominated fund and one US dollar-denominated fund. The company has offices in Beijing, Shanghai, Los Angeles, and San Francisco, and holds a license to operate in the U.S. securities market.

The healthcare and medical sector is a key focus area where Capital Equity holds significant competitive advantages, having ranked for four consecutive years as the new-economy investment bank with the highest number of healthcare industry transactions in China. Meanwhile, Capital Equity boasts the largest, most professional, and most comprehensively integrated healthcare investment banking team in the country.